Nanoscope Therapeutics to Participate in Eyecelerator 2026 and the American Academy of Ophthalmology 2026 Annual Meeting
Chief Medical Officer Dr. Sam Barone to join the Emerging Innovations in Retinal Therapies panel; Company to present an update on MOGENRY® in the Retina Drug Delivery & New Targets Showcase at Eyecelerator 2026 Four-year REMAIN data from the RESTORE Phase 2b/3 trial of MCO-010 in...
Covered in this story
What has happened since
- Moody's Corporation is up 5.1% since this was published, 14 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Moody's Corporation
- Jefferies: $484 → $560 by Oct 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $MCO yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Moody's Corporation →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.